US.BDX · Becton Dickinson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.766218809980806,
        "turnoverUsdM": 272.612208,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.BDX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 147.6528,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.5,
      "take_profit_price": 170.5679,
      "target_multiplier": 2.2,
      "technical_strength": 2.25,
      "take_profit_percent": 9.1
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.6448445739661395,
    "stopLossPercent": 5.532437619961612,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 70.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 62.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 149.436,
    "ma50": 148.0342,
    "close": 156.3,
    "prevClose": 155.54,
    "avgVolume20": 2870328,
    "volumeRatio": 0.61,
    "changePercent": 0.49
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.007152522714092502,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 0.6041448013328761,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.8293427168978547,
      "volat_points": 0,
      "day_range_pct": 0.020537492002559252,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 70.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.9,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 58,
        "contribution": 2.9
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 22.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 75.33,
        "contribution": 22.6
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 62.7,
    "details": [
      "基本面分析總分: 2.9/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 22.6/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.9,
      "資金流": 16.4,
      "市場環境": 8.6,
      "情緒分析": 3,
      "技術信號": 22.6,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 272.612208,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BDX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.57
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 720.4330052000001,
                "ma50": 711.66400144,
                "name": "QQQ",
                "close": 709.42999,
                "points": 0.4
              },
              "spy": {
                "ma20": 741.2935059,
                "ma50": 739.0122021000002,
                "name": "SPY",
                "close": 747.71002,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.766218809980806,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.5
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140778426,
                "url": "https://finnhub.io/api/news?id=67539a3ffd65f04ec9465c4dcd6ed59833c967b2e4269a76cae2a090d82941f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson & Company (NYSE:BDX) is one of the best value stocks to buy right now. On June 23, BD (Becton, Dickinson & Company) announced that its CentroVena One Insertion System was awarded an Innovative Technology contract by Vizient, the nation’s largest provider-driven healthcare performance improvement company. This contract recognizes the system as a breakthrough […]",
                "category": "company",
                "datetime": 1782893774,
                "headline": "BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System"
              },
              {
                "id": 140700270,
                "url": "https://finnhub.io/api/news?id=5b89432e434fe009247d935c3c8a2e43c6b397909c5611218556e42dcbea1227",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. On June 6, 2026, Becton, Dickinson and Company (NYSE:BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep™ Clear 1 mL and FREPP™ Clear 1.5 mL skin preparation applicators due to potential fungal contamination […]",
                "category": "company",
                "datetime": 1782203755,
                "headline": "Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products"
              },
              {
                "id": 140645722,
                "url": "https://finnhub.io/api/news?id=8609db04e140777425e1b39bcadd535acf2b839741f5f4815bf0bf3fcc060be3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.",
                "category": "company",
                "datetime": 1781618040,
                "headline": "Here's Why You Should Retain BDX Stock in Your Portfolio Now"
              },
              {
                "id": 140639688,
                "url": "https://finnhub.io/api/news?id=b6167a56c0e9c0521521909c73758da7d50e843626937611ad6ff903ec1cf4be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) is included among the Top 10 Income Stocks with the Highest Upside Potential. On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe […]",
                "category": "company",
                "datetime": 1781551446,
                "headline": "BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist"
              },
              {
                "id": 140621805,
                "url": "https://finnhub.io/api/news?id=966fc5c3189c46af1ff4e6f2314a3a44cbb05b72609ae11a0df7e36f2c254c9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Is BDX a good stock to buy? We came across a bullish thesis on Becton, Dickinson and Company on The Mispricing Desk’s Substack. In this article, we will summarize the bulls’ thesis on BDX. Becton, Dickinson and Company’s share was trading at $149.99 as of June 8th. BDX’s trailing and forward P/E were 26.38 and 11.21 respectively […]",
                "category": "company",
                "datetime": 1781288239,
                "headline": "Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?"
              }
            ],
            "raw_source": [
              {
                "id": 140835347,
                "url": "https://finnhub.io/api/news?id=7c2ba7baa099679035fad5170d750e7121c1446d52ed53d54af19195f6b4a2f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Don't sleep on these medical device leaders.",
                "category": "company",
                "datetime": 1783461000,
                "headline": "Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom"
              },
              {
                "id": 140830065,
                "url": "https://finnhub.io/api/news?id=3c61c162eeb4a4ff55bbbf7eb416d76bd56a1411992abae065eed559761e61eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.",
                "category": "company",
                "datetime": 1783430548,
                "headline": "How To Target A 10% Yield While Catching The BSX Stock Knife?"
              },
              {
                "id": 140821788,
                "url": "https://finnhub.io/api/news?id=25b3a93687b8f773f29a1dcc1c467908902bb091355627cbd6112d9aabd028a3",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "Evercore ISI Group  analyst Vijay Kumar   maintains Becton Dickinson (NYSE:BDX) with a Outperform and lowers the price target from $190 to $180.",
                "category": "company",
                "datetime": 1783338081,
                "headline": "Evercore ISI Group Maintains Outperform on Becton Dickinson, Lowers Price Target to $180"
              },
              {
                "id": 140802850,
                "url": "https://finnhub.io/api/news?id=c5905c968be2d149392bf23b184b1bb711768e2b822b0fb6621edca56d2e06a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.",
                "category": "company",
                "datetime": 1783100460,
                "headline": "WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?"
              },
              {
                "id": 140794039,
                "url": "https://finnhub.io/api/news?id=8831e57c447685f7d89edb07b4c239f2b6fa697dd0711d22279e85d63efc7d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "While a guidance cut has reset expectations, several core Boston Scientific franchises are accelerating. The Neuromodulation and Interventional Oncology businesses both posted organic sales growth of 15% last quarter. This internal momentum in high-value categories contrasts sharply with the new, more cautious company-wide outlook.",
                "category": "company",
                "datetime": 1783013922,
                "headline": "What Could Push BSX Stock Higher From Here?"
              },
              {
                "id": 140787370,
                "url": "https://finnhub.io/api/news?id=7a79c4dc986fb813b3fed3666730ff4fef46a893a26ce53053e03b57a9e8729c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222722/image_2194222722.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company boasts a few high-margin, high-growth product lines that should fuel a return to sustainable growth. Read why BDX stock is a Buy.",
                "category": "company",
                "datetime": 1782953649,
                "headline": "Becton, Dickinson and Company: Now Is A Great Time To Buy"
              },
              {
                "id": 140780455,
                "url": "https://finnhub.io/api/news?id=aaad818871fc103be361a4ce44426e192688552a3c7b5611a6eda8231c4c61e2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323538000/image_1323538000.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "BDX looks undervalued at 12–13x P/E with 7–8% growth, a 2.78% dividend, buybacks, and debt reduction. Click for more on BDX stock.",
                "category": "company",
                "datetime": 1782905539,
                "headline": "Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There"
              },
              {
                "id": 140778426,
                "url": "https://finnhub.io/api/news?id=67539a3ffd65f04ec9465c4dcd6ed59833c967b2e4269a76cae2a090d82941f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson & Company (NYSE:BDX) is one of the best value stocks to buy right now. On June 23, BD (Becton, Dickinson & Company) announced that its CentroVena One Insertion System was awarded an Innovative Technology contract by Vizient, the nation’s largest provider-driven healthcare performance improvement company. This contract recognizes the system as a breakthrough […]",
                "category": "company",
                "datetime": 1782893774,
                "headline": "BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System"
              },
              {
                "id": 140771662,
                "url": "https://finnhub.io/api/news?id=8a15f5817679e8349c5c9ce173c3041ec8b1477d09f97686cfc439e64e805427",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "The global IV equipment market is set to reach USD 23.92 billion by 2031, expanding from USD 17.82 billion in 2026, at a CAGR of 6.1%. Growth is fueled by rising chronic disease prevalence and increasing hospitalizations, along with a shift towards home-based and outpatient care. Technological advancements such as needle-free connectors and smart infusion pumps are elevating market adoption. North America leads the market, driven by a robust healthcare infrastructure and high adoption of medical",
                "category": "company",
                "datetime": 1782819120,
                "headline": "IV Equipment Market by Type, Application, End User - Global Forecast to 2031"
              },
              {
                "id": 140744963,
                "url": "https://finnhub.io/api/news?id=d502d3e234636610a86a46fb082cae7d5af2639e1594755baf12d54b8bc8d7f9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Aristocrats beat SPY YTD as June rebounds; CAT tops 2026 gains.",
                "category": "company",
                "datetime": 1782541720,
                "headline": "Best Dividend Aristocrats: June 2026"
              },
              {
                "id": 140740729,
                "url": "https://finnhub.io/api/news?id=e2ecfe7423e0385e993151624a54a5d758f2b095b51c5e3aa85f275016df6d8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read it here.",
                "category": "company",
                "datetime": 1782496544,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 28"
              },
              {
                "id": 140714096,
                "url": "https://finnhub.io/api/news?id=754a8afcca3dd80c30d49a98cc380b668565eecd38f701a90dd2f18d5f95a09c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "ABT's Emerging Markets drive EPD growth, with strong branded generics demand, biosimilar expansion and new approvals boosting momentum.",
                "category": "company",
                "datetime": 1782305520,
                "headline": "How Are Emerging Markets Supporting Abbott's EPD Momentum?"
              },
              {
                "id": 140700827,
                "url": "https://finnhub.io/api/news?id=2286fbe11f2f2afef5e244b930221515464b505e20f39e83fb3b2a4fbe259cd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes products with the potential to drive meaningful improvements in healthcare delivery.",
                "category": "company",
                "datetime": 1782211800,
                "headline": "BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System"
              },
              {
                "id": 140700270,
                "url": "https://finnhub.io/api/news?id=5b89432e434fe009247d935c3c8a2e43c6b397909c5611218556e42dcbea1227",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. On June 6, 2026, Becton, Dickinson and Company (NYSE:BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep™ Clear 1 mL and FREPP™ Clear 1.5 mL skin preparation applicators due to potential fungal contamination […]",
                "category": "company",
                "datetime": 1782203755,
                "headline": "Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products"
              },
              {
                "id": 140706559,
                "url": "https://finnhub.io/api/news?id=09e94861b4dfbb61978f6f3f8aca1e9b96be6dd16bd9cdb280880b715ab000d1",
                "image": "",
                "source": "Benzinga",
                "related": "BDX",
                "summary": "The contract was awarded following a review by hospital experts serving on Vizient's client-led councils, and recognizes that CentroVena One™ offers differentiated capabilities through its all-in-one design with the",
                "category": "company",
                "datetime": 1782197702,
                "headline": "Becton Dickinson's CentroVena One Insertion System Awarded Innovative Technology Contract From Vizient; Terms Not Disclosed"
              },
              {
                "id": 140692649,
                "url": "https://finnhub.io/api/news?id=c1919febf4825720827c0628325383cd7fb523d6c425890016fdd2658f909bba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "ABT falls 29.4% YTD as respiratory testing weakness, China uncertainty and acquisition dilution pressure results and outlook.",
                "category": "company",
                "datetime": 1782133800,
                "headline": "How to Approach Abbott Stock Following Its Sharp YTD Decline?"
              },
              {
                "id": 140689843,
                "url": "https://finnhub.io/api/news?id=dfe048026825180c50eebedc507affbc325e7a0c399035a2f62b6328675f7119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Don't wait too long to get in on these outstanding dividend payers.",
                "category": "company",
                "datetime": 1782108300,
                "headline": "3 Excellent Dividend Stocks to Buy on the Dip"
              },
              {
                "id": 140689912,
                "url": "https://finnhub.io/api/news?id=c220c8b93ffe9e8047b1b9d6d27017a0034a9bf856cb5f05aff2f568827b8972",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BDX",
                "summary": "Dividend Kings rebound in June, nearly matching SPY YTD.",
                "category": "company",
                "datetime": 1782101010,
                "headline": "Best Dividend Kings: June 2026"
              },
              {
                "id": 140684373,
                "url": "https://finnhub.io/api/news?id=08a2d8c4a3a84a5b11fda9c9ec4c25f387bf1ae94ec519ce307fcbf709ad06f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "On June 17, 2026, CONMED Corporation announced that John E. Gallagher will become Executive Vice President, Chief Financial Officer, and principal financial and accounting officer from July 15, 2026, succeeding Todd Garner, who will remain in an advisory role until November 2, 2026. Gallagher’s nearly three decades of finance leadership across healthcare and industrial companies, including senior roles at Certara, Cue Health, and Becton Dickinson, signals a refreshed approach to CONMED’s...",
                "category": "company",
                "datetime": 1782040162,
                "headline": "Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?"
              },
              {
                "id": 140664070,
                "url": "https://finnhub.io/api/news?id=6d9943dc90e818f99e50146e5d1610165de152f4f7714dcf9fcf8ff7f8cb4118",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Closed System Drug Transfer Devices Market size & share revenue was valued at approximately USD 1.47 Billion in 2025 and is expected to reach USD 1.58 Billion in 2026 and is expected to reach around USD 3.21 Billion by 2035, at a CAGR of 8.3% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are BD (Becton Dic",
                "category": "company",
                "datetime": 1781803800,
                "headline": "Global Closed System Drug Transfer Devices Market Size/Share Worth USD 3.21 Billion by 2035 at a 8.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)"
              },
              {
                "id": 140645722,
                "url": "https://finnhub.io/api/news?id=8609db04e140777425e1b39bcadd535acf2b839741f5f4815bf0bf3fcc060be3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.",
                "category": "company",
                "datetime": 1781618040,
                "headline": "Here's Why You Should Retain BDX Stock in Your Portfolio Now"
              },
              {
                "id": 140639688,
                "url": "https://finnhub.io/api/news?id=b6167a56c0e9c0521521909c73758da7d50e843626937611ad6ff903ec1cf4be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Becton, Dickinson and Company (NYSE:BDX) is included among the Top 10 Income Stocks with the Highest Upside Potential. On June 12, BofA lowered its price recommendation on Becton, Dickinson and Company (NYSE:BDX) to $170 from $177. It reiterated a Neutral rating on the shares. The analyst noted that the firm’s services team continues to observe […]",
                "category": "company",
                "datetime": 1781551446,
                "headline": "BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist"
              },
              {
                "id": 140621805,
                "url": "https://finnhub.io/api/news?id=966fc5c3189c46af1ff4e6f2314a3a44cbb05b72609ae11a0df7e36f2c254c9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "Is BDX a good stock to buy? We came across a bullish thesis on Becton, Dickinson and Company on The Mispricing Desk’s Substack. In this article, we will summarize the bulls’ thesis on BDX. Becton, Dickinson and Company’s share was trading at $149.99 as of June 8th. BDX’s trailing and forward P/E were 26.38 and 11.21 respectively […]",
                "category": "company",
                "datetime": 1781288239,
                "headline": "Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?"
              },
              {
                "id": 140610644,
                "url": "https://finnhub.io/api/news?id=7dbc7abe2b42b34f244e8173c7ad8e406a62e935db0fd374b77bfc1fbdda0e3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BDX",
                "summary": "While ResMed has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.",
                "category": "company",
                "datetime": 1781184026,
                "headline": "Is ResMed Stock Underperforming the Dow?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 5,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.5,
            "source_article_count": 24,
            "discarded_article_count": 19
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日3日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 2767123.3333333335,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 3374390,
              "avg_vol_20": 2886990,
              "avg_vol_30": 2767123.3333333335,
              "range_pct_10": 0.11906589891234795,
              "range_pct_20": 0.11906589891234795,
              "range_pct_30": 0.11906589891234795,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.2194577521541625,
              "dist_to_20d_high": 0.015246975806451533,
              "down_shrink_days": 3,
              "breakout_level_20d": 158.72,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 1
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.766218809980806,
              "turnoverUsdM": 272.612208,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.BDX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 147.6528,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.5,
            "take_profit_price": 170.5679,
            "target_multiplier": 2.2,
            "technical_strength": 2.25,
            "take_profit_percent": 9.1
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.6448445739661395,
          "stopLossPercent": 5.532437619961612,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 4.3236,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.77
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 126.72
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1449
    },
    "kdj": {
      "d": 77.17,
      "j": 87.9,
      "k": 80.75,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 70
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -2024140,
      "recentSlope": 1695476,
      "previousSlope": -383340
    },
    "rsi": 63.68,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 144.7008,
      "position": "SAR喺價下",
      "distancePct": 7.42,
      "previousTrend": "上升"
    },
    "ma50": 148.0342,
    "macd": {
      "macd": 2.2183531134929524,
      "trend": "強烈看漲",
      "signal": 1.1047241560800556,
      "histogram": 1.1136289574128968
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 149.5457,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.61,
      "score": 2,
      "avgVolume": 2870328,
      "currentVolume": 1744160
    },
    "derived": {
      "ma20": 149.436,
      "ma50": 148.0342,
      "prevClose": 155.54,
      "avgVolume10": 3184546,
      "avgVolume20": 2870328,
      "changePercent": 0.49,
      "avgVolumeForScore": 2870328
    },
    "ma_cross": {
      "ma20": 149.436,
      "ma50": 148.0342,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 149.179,
      "prevMa50": 148.0052,
      "spreadPct": 0.95,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 139.3172,
      "upper": 159.5548,
      "position": "上半部"
    },
    "rsi_short": 51.3,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.61
    }
  }
}

{
  "close": 156.3,
  "volume": 1744160,
  "changePercent": 0.49
}